✦ LIBER ✦

TREATMENT OF PLASMA CELL LEUKAEMIA AND RESISTANT/RELAPSED MULTIPLE MYELOMA WITH VINCRISTINE, MITOXANTRONE AND DEXAMETHASONE (VMD PROTOCOL)

✍ Scribed by Pellegrino Musto; Michele Mario Greco; Antonietta Falcone; Mario Carotenuto

Book ID: 114712628
Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 198 KB
Volume: 79
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.1991.tb08101.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of melphalan-resistant multipl

Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD)

✍ Bladé, Joan; Miguel, Jesús San; Sanz-Sanz, Miguel Angel; Alcalá, Antonio; Hernán 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 540 KB

A staged approach with vincristine, adri

A staged approach with vincristine, adriamycin, and dexamethasone followed by bortezomib, thalidomide, and dexamethasone before autologous hematopoietic stem cell transplantation in the treatment of newly diagnosed multiple myeloma

✍ C. S. Chim; A. K. W. Lie; E. Y. T. Chan; Y. Y. Leung; S. C. W. Cheung; S. Y. T. 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 319 KB

Treatment of primary resistant or relaps

Treatment of primary resistant or relapsed multiple myeloma with high-dose chemoradiotherapy, hematopoietic stem cell rescue, and granulocyte-macrophage colony-stimulating factor

✍ David P. Schenkein; Yener Koc; Thierry Alcindor; Edward A. Stadtmauer; Kenneth B 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 210 KB

Cyclophosphamide plus dexamethasone is a

Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma : Results of a randomized comparison with vincristine, doxorubicin, and dexamethasone

✍ Ulf-Henrik Mellqvist; Stig Lenhoff; Hans E. Johnsen; Martin Hjorth; Erik Holmber 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 2 views

## Abstract ## BACKGROUND Today, intensive therapy that includes high‐dose melphalan with autologous stem cell transplantation (ASCT) is considered standard therapy in younger patients with newly diagnosed myeloma. When the current trial was initiated, combined vincristine, doxorubicin, and dexame

Unusual cutaneous involvement during pla

Unusual cutaneous involvement during plasma cell leukaemia phase in a multiple myeloma patient after treatment with thalidomide: a case report and review of the literature

✍ D. T. Alexandrescu; L. Koulova; P. H. Wiernik 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 291 KB